ArticleHealth science reports2025
Plasminogen as a Marker for Assessing Thrombotic Risk During Hepatitis in Cameroon: Case-Control Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hepatic Enzyme Abnormalities and Their Association With Hematological Parameters in Sickle Cell Disease: A Case-Control Study in Cameroon.Health science reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The liver synthesizes coagulation factors, anticoagulants, proteins involved in fibrinolysis, and the platelet production regulator, thrombopoietin, from megakaryocytes. Importantly, hepatic dysfunction that arises from hepatitis may perturb the clotting process. This study aims to determine these patients' plasminogen levels and hemostasis disorders to assess the thrombotic risk. Methods: An analytical case-control study was carried out over 6 months. The study included hepatitis B, C, and D patients from Bafoussam Regional Hospital and Laquinitie Hospital in Douala-Cameroon, compared to healthy controls, to evaluate differences in hemostasis and thrombotic risk. Control tests were performed using the immunochromatographic and ELISA methods. Blood Count was performed by flow cytometry method. And determination of d-dimer and plasminogen by nephelometry and ELISA respectively; finally the evaluation of the enzymatic activity of alanine aminotransferase and aspartate aminotransferase (ALT and AST) by the spectrophotometric kinetic method. The results were recorded in an Excel spreadsheet and analyzed using the statistical software R version 4.1.1. Results: The population size was 340 participants including 162 controls (47.7%) and 178 (52.3%) cases of which 136 cases of hepatitis B (76.4%), 26 cases of hepatitis C (14.6%), and 16 cases of hepatitis D (9%). The sex ratio was 3.15 in favor of men; including 1.7 in cases and 9.1 in controls. All patients had a thrombotic risk characterized by a decrease in plasminogen levels compared to controls ( Conclusion: This study shows a decrease in plasminogen in patients during hepatitis. It suggests it is an important element to evaluate the thrombotic risk although the exploration of other coagulation tests should be associated with it for a complete and exhaustive evaluation and a better final diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.